EVAX
NASDAQEvaxion A/S
Price$3.43+0.33 (+10.65%)
2026-03-042026-06-05
News · 26 weeks55-100%
2025-12-142026-06-07
Mix4090d
- Insider16(40%)
- SEC Filings13(33%)
- Other9(23%)
- Earnings1(3%)
- Offering1(3%)
Latest news
25 items- SECSEC Form 6-K filed by Evaxion A/S6-K - Evaxion A/S (0001828253) (Filer)
- PREvaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 CongressData will reflect the functional characterization of EVX-04Poster presentation on June 13, 2026 COPENHAGEN, Denmark, May 12, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will announce the functional characterization of EVX-04, an off-the-shelf therapeutic acute myeloid leukemia (AML) vaccine, in a poster presentation at the European Hematology Association (EHA) 2026 Congress taking place in Stockholm, Sweden, June 11-14, 2026. The new preclinical data will represent another step towards clinical testing of EVX-04. Evaxion plans to submit a clinical trial application in the second half o
- SECSEC Form 6-K filed by Evaxion A/S6-K - Evaxion A/S (0001828253) (Filer)
- PREvaxion announces business update and first quarter 2026 financial resultsCOPENHAGEN, Denmark, May 7, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and announces first quarter 2026 financial results. Business highlights (since last quarterly update)Evaxion has had a good start to the year executing on our plans and achieving our first milestone for 2026 as expected. Highlights include: New data demonstrating an 86% vaccine target recognition by AI-Immunology™ in personalized cancer vaccine EVX-01 is a further scientific validation of the platform's precision in driving immune response. This marked our first milestone for the yearAnothe
- SECSEC Form 6-K filed by Evaxion A/S6-K - Evaxion A/S (0001828253) (Filer)
- PREvaxion to announce business update and first quarter 2026 financial results on May 7, 2026COPENHAGEN, Denmark, May 4, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and report its first quarter 2026 financial results on Thursday May 7, 2026, before opening of the Nasdaq CM. Evaxion's Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numbers and a unique PIN code. The call can be acces
- SECSEC Form 6-K filed by Evaxion A/S6-K - Evaxion A/S (0001828253) (Filer)
- PREvaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating OfficerManagement remit expansion reflecting organization alignment to maximize external engagement and strategy execution COPENHAGEN, Denmark, April 27, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, that Birgitte Rønø, its Chief Scientific Officer (CSO), will take on the dual responsibilities of CSO and Chief Operating Officer (COO). The promotion follows an internal management review of the optimal way of working to continue to deliver Evaxion's strategy through broader external visibility of the power of the AI-Immunology™ platform with partners and investors. It also reflects the recognitio
- INSIDERNew insider Bitsch-Norhave Jens claimed ownership of 2,376 units of Ordinary Shares (SEC Form 3)3 - Evaxion A/S (0001828253) (Issuer)
- SECSEC Form 6-K filed by Evaxion A/S6-K - Evaxion A/S (0001828253) (Filer)
- SECSEC Form 6-K filed by Evaxion A/S6-K - Evaxion A/S (0001828253) (Filer)
- SECSEC Form 6-K filed by Evaxion A/S6-K - Evaxion A/S (0001828253) (Filer)
- PREvaxion's AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trialNew phase 2 data from personalized cancer vaccine EVX-01 demonstrates a record-high rate of vaccine targets triggering a tumor-specific immune responseThe results reinforce that Evaxion's pioneering AI platform, AI-Immunology™ accurately identifies and selects the most relevant vaccine targetsData will be presented at the American Association for Cancer Research (AACR) Annual Meeting COPENHAGEN, Denmark, April 17, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces new data demonstrating that AI-Immunology™ identifies and selects the most therapeutically relevant vaccine targets. The
- PRNew data demonstrates the unique scalability of Evaxion's AI-Immunology™ platform in glioblastomaData analysis conducted in collaboration with a leading academic medical center shows that AI‑Immunology™ enables vaccine design also for the deadly brain cancer, glioblastomaUniquely, the platform can identify a novel source of targets to include in glioblastoma cancer vaccines, potentially enhancing their efficacyData will be presented at the American Association for Cancer Research (AACR) Annual Meeting COPENHAGEN, Denmark, April 17, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces new data demonstrating the platform's ability to also potentially develop vaccines for glioblastom
- SECSEC Form 6-K filed by Evaxion A/S6-K - Evaxion A/S (0001828253) (Filer)
- PREvaxion concludes Annual General MeetingCOPENHAGEN, Denmark, April 16, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, held its Annual General Meeting today at the company's offices. The 2025 Annual Report was approved and the Board of Directors' proposals passed. Marianne Søgaard, Lars Holtug, Lars Aage Staal Wegner and Roberto Prego Pineda were re-elected to the Board of Directors. Jens Bitsch Nørhave was elected to the Board of Directors. Minutes from the meeting can be found on our website. Contact information Evaxion A/S Mads Kronborg Vice President, Investor Relations & Communication +45 53 54 82 96 mak@evaxion.ai Abo
- INSIDERAmendment: SEC Form 3 filed by new insider Mattsson Andreas Holm3/A - Evaxion A/S (0001828253) (Issuer)
- SECSEC Form 6-K filed by Evaxion A/S6-K - Evaxion A/S (0001828253) (Filer)
- PREvaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01Trial extension completed as planned with three-year clinical efficacy data expected to be presented in the second half of 2026The trial has already yielded encouraging one- and two-year data including a 75% Objective Response Rate COPENHAGEN, Denmark, April 7, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, has successfully completed the one-year extension of its phase 2 trial with personalized cancer vaccine EVX-01 with the last patient having now had last physician visit. Patients in the trial will continue to be monitored and data prepared for expected presentation in the second half of
- INSIDERAmendment: SEC Form 3 filed by new insider Soegaard Marianne3/A - Evaxion A/S (0001828253) (Issuer)
- INSIDERAmendment: SEC Form 3 filed by new insider Wegner Lars Aage Staal3/A - Evaxion A/S (0001828253) (Issuer)
- INSIDERAmendment: SEC Form 3 filed by new insider Tayton-Martin Helen Katrina3/A - Evaxion A/S (0001828253) (Issuer)
- SECSEC Form 6-K filed by Evaxion A/S6-K - Evaxion A/S (0001828253) (Filer)
- PREvaxion to present novel AI-based polio vaccine design concepts at the World Vaccine CongressUsing its pioneering AI-platform, AI-Immunology™, Evaxion has, in collaboration with the Gates Foundation, developed novel design concepts for polio vaccines potentially superior to those currently usedThe AI-Immunology™ concepts include hybrid capsid designs and de novo designed B-cell antigen approachesDespite polio vaccines being available for decades, the highly infectious viral disease continues to pose a global health riskEvaxion will also present data from its EVX-V1 vaccine program targeting cytomegalovirus at the World Vaccine Congress COPENHAGEN, Denmark, March 30, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pio
- INSIDERAmendment: SEC Form 3 filed by new insider Rono Birgitte3/A - Evaxion A/S (0001828253) (Issuer)
EVAX FAQ
7 questionsWhat does Evaxion A/S do?
Evaxion Biotech A/S, a clinical-stage artificial intelligence-immunology platform company, identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. The company develops therapies using PIONEER, an immuno-oncology platform; EDEN, a bacterial disease platform; and RAVENTM, a viral disease platform. It develops EVX-01, a novel liposomal, peptide-based cancer immunotherapy that is in clinical Phase I/IIa trial for indications, such as metastatic and/or unresectable melanoma, non-small cell lung cancer, and bladder cancer...Where does EVAX stock trade?
Evaxion A/S (EVAX) is listed on NASDAQ.What sector and industry is EVAX in?
Evaxion A/S operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Evaxion A/S go public?
Evaxion A/S (EVAX) completed its IPO in 2021.What are analysts saying about EVAX?
Evaxion A/S has had 3 recent analyst actions on file. The most recent action was from Maxim Group: Buy with a $1000.00 price target on 2026-02-19. Recent price targets range from $800.00 to $1400.00.What companies are similar to EVAX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare EVAX side-by-side with any of them on Quantisnow.How can I track EVAX on Quantisnow?
Quantisnow aggregates Evaxion A/S's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow EVAX to receive live email and push alerts on every new disclosure.